Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-duration ibrutinib plus obinutuzumab in treatment-naive CLL
2021-000311-23Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Bone marrow minimal residual disease negativity at 30-day follow-up. Started Jun 2021; status: active.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2021-000311-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000311-23.